Halyard Health Inc. (NYSE:HYH) has been assigned a consensus recommendation of “Buy” from the eight analysts that are covering the stock. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $34.75.
Several analysts have commented on the stock. Stifel Nicolaus raised their target price on shares of Halyard Health from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Tuesday, June 14th. TheStreet upgraded shares of Halyard Health from a “sell” rating to a “hold” rating in a report on Friday, July 8th. Finally, Deutsche Bank AG raised their target price on shares of Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, August 10th.
Shares of Halyard Health (NYSE:HYH) opened at 34.66 on Tuesday. The stock has a 50 day moving average of $35.51 and a 200-day moving average of $32.43. The firm’s market capitalization is $1.62 billion. Halyard Health has a 52 week low of $22.76 and a 52 week high of $37.31.
Halyard Health (NYSE:HYH) last announced its earnings results on Wednesday, August 3rd. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.36 by $0.09. The firm had revenue of $400 million for the quarter, compared to the consensus estimate of $383.08 million. Halyard Health had a negative net margin of 27.63% and a positive return on equity of 8.91%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS. Equities analysts anticipate that Halyard Health will post $1.82 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of HYH. IFP Advisors Inc boosted its position in shares of Halyard Health by 1.9% in the second quarter. IFP Advisors Inc now owns 3,141 shares of the company’s stock valued at $102,000 after buying an additional 58 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Halyard Health during the second quarter valued at $104,000. LS Investment Advisors LLC boosted its position in shares of Halyard Health by 25.6% in the second quarter. LS Investment Advisors LLC now owns 3,241 shares of the company’s stock valued at $105,000 after buying an additional 661 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Halyard Health during the second quarter valued at $109,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Halyard Health during the second quarter valued at $182,000. 82.94% of the stock is owned by institutional investors.
Halyard Health Company Profile
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.